BUZZ-Hims & Hers rises after BTIG starts coverage with 'buy' rating

Telehealth firm Hims & Hers Health's HIMS.N shares rise 1.23% to $27.23 premarket

Brokerage BTIG starts coverage with buy rating, PT $35

Says co is "disrupting healthcare with tech and convenience"

Unlike pure tele-health platforms that rely on remote visits, HIMS offers access to medications and treatment plans, so company is better insulated from the risk of more people returning to in-person visits - brokerage

BTIG estimates that over 50% of HIMS' members have a personalized treatment plan

Expects revenue growth and demand for GLP-1 and other obesity health products to remain robust

We believe compounding for GLP-1s is here to stay - BTIG

HIMS offers compounded versions of Novo Nordisk's NOVOb.CO Wegovy and Ozempic

Stock more than doubled last year

(Reporting by Sriparna Roy)